Loading verified market, valuation, and statement data.
2. Company Fundamentals
2.1 Competitiveness
| Metric |
Value |
| Operating Margins |
18.95% |
| Profit Margins |
17.81% |
| Return on Equity |
45.22% |
| Return on Assets |
7.52% |
| Free Float |
0.26B |
| Dividend Yield |
1.87% |
| Short Int % Utilisation |
0.01% |
2.2 Growth
| Metric |
Value |
| Revenue Growth |
3.0% |
| Free Cash Flow |
12.43B |
| EBITDA |
4.15 (Ratio) |
| Enterprise Value |
61.56B |
| EV/Revenue |
0.9 |
| EV/EBITDA |
4.15 |
Revenue growth of 3.0% suggests mature or challenged top-line momentum.
2.3 Management
| Role |
Metric |
| Consensus Rating |
N/A |
2.4 Return
| Metric |
Value |
| Expected Return (Ann.)* |
33.58% |
| Risk / Std Dev (Ann.)* |
24.99% |
| 1-Year Price Return* |
28.96% |
Latest Market Data (as of 2026-08-14, US Eastern time):
| Metric |
Value |
| Last Price |
$261.41 |
| 52-Week Range |
$188.08 – $277.22 |
| Observation Count |
249 trading days |
The return and risk statistics use daily adjusted closes from the retrieved one-year series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.
2.5 FCFF DCF Valuation
FCFF DCF exception: FCFF DCF is not the primary valuation method for financial institutions or REITs. This post deliberately does not publish a mechanical enterprise value or implied per-share value on an unsuitable basis.
| Available valuation input |
Value |
| Last market price |
$263.20 |
| Market capitalisation |
$66.55B |
| Revenue |
$67.07B |
| EBIT |
$13.55B |
| Reported free cash flow |
$9.88B |
| FCF yield |
14.85% |
| Net debt / EBITDA |
NM |
2.6 Investor-Style Research Screen
| Educational screen |
Result |
| Buffett-inspired cash-quality checks |
not rated — FCFF DCF suitability or data-integrity condition not met |
| Lynch-inspired balance-and-growth checks |
not rated — FCFF DCF suitability or data-integrity condition not met |
Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 17:21:47.401788 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Financial institutions and REITs require sector-specific methods rather than a mechanical FCFF DCF. This is research and analysis only, not personalized financial advice.
2.7 Quantitative Factor Diagnostics
Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.
| Estimation input |
Value |
| Regional factor set |
US |
| Factor-return currency |
USD |
| Issuer-return basis |
USD adjusted total return |
| Estimation window |
2025-08-19 to 2026-06-30 |
| Aligned daily observations |
217 |
| Minimum observation requirement |
120 |
| Currency conversion for HK listings |
not required |
Fama–French Three-Factor and Five-Factor Results
| Diagnostic |
FF3 |
FF5 |
| Annualised alpha |
9.47% |
30.47% |
| Adjusted R² |
0.07 |
0.17 |
| Annualised residual volatility |
22.56% |
21.18% |
| Factor loading (t-statistic) |
FF3 |
FF5 |
| Market excess return (Mkt-RF) |
-0.14 (-1.08) |
0.22 (1.51) |
| Size (SMB) |
0.23 (1.30) |
0.36 (1.95) |
| Value (HML) |
0.44 (2.88) |
0.21 (1.18) |
| Profitability (RMW) |
NM |
0.76 (5.02) |
| Investment (CMA) |
NM |
0.17 (0.64) |
Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.